• Regulatory
A1M Pharma has initiated a collaboration with Antaros Medical to conduct a study in humans undergoing radiation therapy (Peptide Receptor Radionuclide Therapy, PRRT) of neuroendocrine tumours. The purpose of the study is to examine – using magnetic resonance imaging (MRI) and positron emission tomography (PET) – the harmful effects that the radiation in PRRT has on the kidneys and the bone marrow. Data from the study will form the basis of the company's upcoming clinical studies.

– With this study, we are now initiating our clinical program which is an important step forward. The study will provide us with valuable data, which will enable us to design our upcoming clinical phase I/II study in the best way possible. We continue to prepare for the clinical study according to plan, says A1M Pharma's Head of Development, Eddie Thordarson.

The study will be conducted at the Uppsala University Hospital, on patients that are treated with the targeted radiation therapy PRRT. The radiation therapy puts a strain on the patient's kidneys, with the risk of kidney injuries at a later stage. Today, kidney injuries and bone marrow injuries are the limiting factors of the maximum radiation dose that can be used during the radiation treatment, as well as the frequency of the treatments. On several occasions during the study, the patients will be examined with a magnetic resonance (MRI) and PET scanner for quick detection of changes in the organs occurring during the radiation therapy.

– PRRT causes kidney injuries, but the effects are usually not detectable right away and can stay hidden until later. If we can detect these harmful effects early on, using advanced imaging techniques, we will be able to predict the future more accurately. Our goal is to detect the harmful effects at an early stage, so that we can see the effects of our drug candidate ROSgard™ as early as possible in phase I/II, says Eddie Thordarson.

The study is scheduled to start during the first quarter of 2018, and it is expected to be completed in last quarter of 2019. A1M Pharma will receive frequent updates during the course of the study.

About Antaros Medical
Antaros Medical is a clinical research company, focusing on developing innovative techniques and tailor-made studies within imaging. The aim is to study pharmaceutical effects on different organ systems in the human body, and the company specializes in cardiometabolic diseases (including NAFLD/NASH and chronic kidney disease) and oncology, which will enable improved evidence based decision making in clinical drug development. The company has a global network of partners and clients, including large and small pharmaceutical companies, and is also a partner in several European research centers, such as Innovative Medicine Initiative (IMI) and European Cooperation in Science and Technology (COST). More information is available at: www.antarosmedical.com

For more information, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.

For more information, please contact
Tomas Eriksson, CEO
Telephone: +46 46-286 50 30
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

About A1M Pharma
Several preclinical studies indicate that A1M Pharma's candidate drug, ROSgard™, based on the endogenous protein Alpha- 1-Microglobulin, restores impairments to kidney function by repairing damaged tissue and protecting against oxidative stress. Kidney injury is a condition which often occurs in connection with preeclampsia and which often limits the possibilities of using radiation therapies as a treatment for cancer. The company's two indications are kidney protection in connection with Peptide Receptor Radionuclide Therapy (PRRT) - a targeted radiation therapy for cancer - with the aim of opening the possibility of increasing treatment levels and so fight metastatic cancer more effectively as well as treatment of preeclampsia. Every year, over 12 million people are affected by acute kidney injuries that can lead to permanent kidney damage. Preeclampsia affects around 10 million pregnant women worldwide and is responsible for 76,000 maternal and 500,000 infant deaths each year. A1M Pharma is listed on Nasdaq First North Stockholm since 20 June 2017. A1M Pharma's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.

This information is information that A1M Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was provided, through the above contact, for publication on the 5 January 2018 at 08.10
A1M Pharma AB | Scheelevägen 22 | 223 63 Lund
+46 46 286 50 30 | info@a1m.se
Medlem av Preeclampsia Foundation
Legal disclaimer | © Copyright - A1M